The agreement allows Fukuda Denshi to incorporate the noninvasive blood constituent measurement capabilities of Masimo Rainbow SET to detect and treat life-threatening conditions earlier.

The noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO Oximetry allow for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index, and measure-through motion pulse oximetry.

With Masimo Rainbow SET, the ability to detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, perfusion, saturation, and pulse rate continuously can help save lives and improve patient outcomes.

Kotaro Fukuda, president and CEO, said: “Our overriding goal is to provide innovative medical devices with superior performance and value. The integration of Masimo Rainbow SET Pulse CO-Oximetry measurements will allow us to design and manufacture state-of-the-art patient monitors that advance the delivery of healthcare. Our combined product offering will allow clinicians to more thoroughly assess a patient’s physiological status and make better clinical and treatment decisions.”

Rick Fishel, president of OEM, said: “Fukuda Denshi is the first patient monitoring manufacturer in Japan to integrate Masimo Rainbow SET Pulse CO-Oximetry technology. This first-to-market commitment and strategy provides Fukuda Denshi customers with access to an upgradeable platform of blood constituent monitoring parameters, leveraging additional clinical intelligence and vital noninvasive blood constituent data on their multiparameter patient monitor.”